Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2024-515539-31-00 | Registry Identifier | EU CT | |
| U1111-1309-3391 | Registry Identifier | UTN | |
| jRCT2031240682 | Registry Identifier | jRCT | |
| MK-1167-008 | Other Identifier | MSD |
Not provided
Not provided
Not provided
Termination Notes: Business reason
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia.
The goals of this study are to learn:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MK-1167 3 mg | Experimental | Participants receive 3 mg of MK-1167 once daily (QD) for up to approximately 24 weeks. |
|
| MK-1167 1 mg | Experimental | Participants receive 1 mg of MK-1167 QD for up to approximately 24 weeks. |
|
| MK-1167 0.3 mg | Experimental | Participants take 0.3 mg of MK-1167 QD for up to approximately 24 weeks. |
|
| Placebo | Placebo Comparator | Participants take placebo QD for up to approximately 24 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK-1167 | Drug | MK-1167 oral capsule |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in the Alzheimer's Disease Assessment Scale-11-item Cognitive Subscale (ADAS-Cog11) Total Score at Week 24 | The change from baseline in ADAS-Cog11 score at Week 24 is presented. ADAS-Cog11 is a structured scale that evaluates memory, orientation, attention, reasoning, language, and constructional praxis. ADAS-Cog11 measures cognition by assessing 11 metrics impaired in AD: word recall; commands; constructional praxis; naming objects and fingers; ideational praxis; orientation; word recognition; remembering test instructions; spoken language ability; word-finding difficulty; and comprehension of spoken language. The total possible score ranges from 0 to 70, with higher scores indicating greater cognitive impairment. Negative values indicate improvement relative to baseline, and vice versa. | Baseline and up to approximately 24 weeks |
| Number of Participants Who Experience One or More Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported. | Up to approximately 28 weeks |
| Number of Participants Who Discontinue Study Intervention Due to an AE | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported. | Up to approximately 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) Overall Score at Week 24 | The overall score in ADCS-CGIC at Week 24 is presented. The ADCS-CGIC is a clinician-rated measure of change in global severity from baseline, scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. The assessment focuses on clinicians' observations of change in the participant's cognitive, functional, and behavioral performance since the beginning of the study. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Banner Alzheimer's Institute ( Site 0110) | Phoenix | Arizona | 85006 | United States | ||
| Irvine Clinical Research ( Site 0104) |
Not provided
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
| Plain Language Summary | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo oral capsule |
|
| Baseline and up to approximately 24 weeks |
| Change From Baseline in The Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Total Score at Week 24 | The change from baseline in ADCS-ADL score at Week 24 is presented. The ADCS-ADL is an informant-based measure of the participant's functional ability in activities of daily living (ADLs). The ADCS-ADL assesses the competence of participants with AD dementia in basic and instrumental ADLs. The ADCS-ADL is a 23-item scale that includes 6 basic ADL items and 17 instrumental ADL items that provide a total score ranging from 0 to 78, with a lower score indicating greater severity. | Baseline and up to approximately 24 weeks |
| Change From Baseline in the ADAS-Cog11 Total Score at Week 12 | The change from baseline in ADAS-Cog11 score at Week 12 is presented. ADAS-Cog11 is a structured scale that evaluates memory, orientation, attention, reasoning, language, and constructional praxis. ADAS-Cog11 measures cognition by assessing 11 metrics impaired in AD: word recall; commands; constructional praxis; naming objects and fingers; ideational praxis; orientation; word recognition; remembering test instructions; spoken language ability; word-finding difficulty; and comprehension of spoken language. The total possible score ranges from 0 to 70, with higher scores indicating greater cognitive impairment. Negative values indicate improvement relative to baseline, and vice versa. | Baseline and up to approximately 12 weeks |
| ADCS-CGIC Overall Score at Week 12 | The overall score in ADCS-CGIC at Week 12 is presented. The ADCS-CGIC is a clinician-rated measure of change in global severity from baseline, scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. The assessment focuses on clinicians' observations of change in the participant's cognitive, functional, and behavioral performance since the beginning of the study. | Baseline and up to approximately 12 weeks |
| Change From Baseline in the ADCS-ADL Total Score at Week 12 | The change from baseline in ADCS-ADL score at Week 12 is presented. The ADCS-ADL is an informant-based measure of the participant's functional ability in activities of daily living (ADLs). The ADCS-ADL assesses the competence of participants with AD dementia in basic and instrumental ADLs. The ADCS-ADL is a 23-item scale that includes 6 basic ADL items and 17 instrumental ADL items that provide a total score ranging from 0 to 78, with a lower score indicating greater severity. | Baseline and up to approximately 12 weeks |
| Irvine |
| California |
| 92614 |
| United States |
| Anderson Clinical Research ( Site 0164) | Redlands | California | 92374 | United States |
| California Neuroscience Research ( Site 0118) | Sherman Oaks | California | 91403 | United States |
| JEM Research Institute / Headlands Research Network ( Site 0108) | Atlantis | Florida | 33462 | United States |
| Brain Matters Research-Neurology ( Site 0150) | Delray Beach | Florida | 33445 | United States |
| Neuropsychiatric Research Center of Southwest Florida ( Site 0152) | Fort Myers | Florida | 33912 | United States |
| Indago Research & Health Center, Inc ( Site 0128) | Hialeah | Florida | 33012 | United States |
| K2 Medical Research THE VILLAGES ( Site 0166) | Lady Lake | Florida | 32159 | United States |
| K2 Medical Research ( Site 0103) | Maitland | Florida | 32750 | United States |
| Premier Clinical Research Institute ( Site 0114) | Miami | Florida | 33122 | United States |
| Aqualane Clinical Research ( Site 0116) | Naples | Florida | 34105 | United States |
| Headlands Research Orlando ( Site 0169) | Orlando | Florida | 32806 | United States |
| Brain Matters Research ( Site 0151) | Stuart | Florida | 34997 | United States |
| K2 Medical Research ( Site 0165) | Tampa | Florida | 33634 | United States |
| Columbus Memory Center ( Site 0197) | Columbus | Georgia | 31909 | United States |
| CenExel iResearch, LLC ( Site 0134) | Savannah | Georgia | 31405 | United States |
| Tandem Clinical Research ( Site 0101) | Marrero | Louisiana | 70072 | United States |
| Pharmasite Research, Inc. ( Site 0167) | Baltimore | Maryland | 21208 | United States |
| Quest Research Institute ( Site 0173) | Farmington Hills | Michigan | 48334 | United States |
| Velocity Clinical Research, Syracuse ( Site 0125) | East Syracuse | New York | 13057 | United States |
| Mid Hudson Medical Research ( Site 0191) | New Windsor | New York | 12553 | United States |
| Flourish Research - Charlotte ( Site 0106) | Matthews | North Carolina | 28105 | United States |
| Velocity Clinical Research - Raleigh ( Site 0123) | Raleigh | North Carolina | 27607 | United States |
| Summit Research Network ( Site 0111) | Portland | Oregon | 97210 | United States |
| Kerwin Medical Center ( Site 0159) | Dallas | Texas | 75231 | United States |
| Grayline Research Center ( Site 0105) | Wichita Falls | Texas | 76309 | United States |
| Northwest Clinical Research Center ( Site 0102) | Bellevue | Washington | 98007 | United States |
| Instituto de Investigaciones Clínicas Mar del Plata ( Site 0207) | Mar del Plata | Buenos Aires | B7600FZN | Argentina |
| Hospital Italiano de Buenos Aires ( Site 0209) | Buenos Aires | Buenos Aires F.D. | C1199ABD | Argentina |
| Instituto Geriatrico Nuestra Señora de Las Nieves ( Site 0208) | Buenos Aires | Buenos Aires F.D. | C1427CCP | Argentina |
| Organizacion Medica de Investigacion - OMI S.A. ( Site 0204) | Buenos Aires | C1015ABO | Argentina |
| Instituto Kremer ( Site 0202) | Córdoba | X5004AOA | Argentina |
| Okanagan Clinical Trials ( Site 0001) | Kelowna | British Columbia | V1Y 1Z9 | Canada |
| Ottawa Memory Clinic ( Site 0004) | Ottawa | Ontario | K1Z 1G3 | Canada |
| Toronto Memory Program ( Site 0006) | Toronto | Ontario | M3B 2S7 | Canada |
| Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico-UOSD Malattie Neurodegenerative ( Site 0903) | Milan | Lombardy | 20122 | Italy |
| Fondazione IRCCS San Gerardo dei Tintori ( Site 0902) | Monza | Monza E Brianza | 20900 | Italy |
| Centro S Giovanni Di Dio Fatebenefratelli ( Site 0904) | Brescia | 25125 | Italy |
| Ospedale San Raffaele. ( Site 0901) | Milan | 20132 | Italy |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0905) | Roma | 00168 | Italy |
| Association of Healthcare Corporation Koukankai Koukan Clinic ( Site 1510) | Kawasaki | Kanagawa | 210-0852 | Japan |
| Kawasaki Saiwai Clinic ( Site 1501) | Kawasaki | Kanagawa | 212-0016 | Japan |
| Hatsuta Neurology Clinic ( Site 1507) | Hirakata | Osaka | 573-1121 | Japan |
| Nagomi Clinic ( Site 1506) | Toyonaka | Osaka | 560-0004 | Japan |
| Takesato Hospital ( Site 1522) | Kasukabe | Saitama | 344-0036 | Japan |
| Iwaki Clinic ( Site 1518) | Anan | Tokushima | 774-0014 | Japan |
| Enomoto Internal Medicine Clinic(Chofu) ( Site 1503) | Chōfu | Tokyo | 182-0036 | Japan |
| Nozomi Memory Clinic ( Site 1504) | Mitaka | Tokyo | 181-0013 | Japan |
| Tokyo Metropolitan Institute for Geriatrics and Gerontology ( Site 1515) | tabashi City | Tokyo | 173-0015 | Japan |
| Itsuki Hospital ( Site 1502) | Tokushima | 770-0852 | Japan |
| Brain Research Center Den Bosch B.V. ( Site 1002) | 's-Hertogenbosch | North Brabant | 5223 LA | Netherlands |
| Brain Research Center. ( Site 1001) | Amsterdam | North Holland | 1081 GN | Netherlands |
| Brain Research Center Zwolle ( Site 1003) | Zwolle | Overijssel | 8025 AZ | Netherlands |
| Inha University Hospital ( Site 1601) | Incheon | 22332 | South Korea |
| Seoul National University Hospital ( Site 1604) | Seoul | 03080 | South Korea |
| Hanyang University Seoul Hospital ( Site 1605) | Seoul | 04763 | South Korea |
| Asan Medical Center ( Site 1603) | Seoul | 05505 | South Korea |
| Centro de Atención Especializada Oroitu ( Site 1211) | Algorta | Bizkaia | 48993 | Spain |
| Hospital de la Santa Creu i Sant Pau ( Site 1204) | Barcelona | Catalonia | 8025 | Spain |
| Hospital Universitario 12 de Octubre ( Site 1208) | Madrid | Madrid, Comunidad de | 28041 | Spain |
| Hospital Universitari i Politecnic La Fe ( Site 1202) | Valencia | Valencia | 46026 | Spain |
| Fundació ACE ( Site 1206) | Barcelona | 08034 | Spain |
| Hospital Universitari Vall D Hebron ( Site 1203) | Barcelona | 08035 | Spain |
| Hospital Universitario Virgen de la Macarena ( Site 1210) | Seville | 41009 | Spain |
| Brain Sciences Scotland Life Sciences-Aberdeen ( Site 1402) | Aberdeen | Aberdeen City | AB25 2XE | United Kingdom |
| Scottish Brain Sciences ( Site 1401) | Edinburgh | Edinburgh, City of | EH12 5PJ | United Kingdom |
| Moorgreen Hospital ( Site 1409) | Southampton | Hampshire | SO30 3JB | United Kingdom |
| Remind UK ( Site 1404) | Bath | Somerset | BA1 3NG | United Kingdom |
| Re:Cognition Health - Birmingham ( Site 1406) | Birmingham | B16 8LT | United Kingdom |
| Windsor Research Unit ( Site 1403) | Cambridge | CB21 5EF | United Kingdom |
| Campus for Ageing and Vitality ( Site 1408) | Newcastle upon Tyne | NE4 5PL | United Kingdom |
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D003704 | Dementia |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided